96% of people who get the vaccine against Pfizer have in common
New research show this remarkable result for Pfizer's Covid shot.
Now that vaccination rates havestarted slowing down In the United States, you may have a better chance of choosing exactly what vaccine you want by configuring your appointment at a specific location. Fortunately, experts say that allThree vaccines Authorized for emergency use in the United States are safe and efficient and that several studies have confirmed this. However, a new discovery can make the pfizer vaccine even more promising: the research found that 96% of people who get the anti-Pfizer vaccine develop COVID antibodies after a single dose.
RELATED:The Pfizer vaccine protects you at least this long study discovery.
Researchers from College London University and the National Health Service (NHS)analyzed antibody response With more than 8,500 people from England and Wales who received the Pfizer or AstraZeneca vaccine and did not have any antibodies before shooting. They published the preliminary results of their study on May 14th.
According to their conclusions, 96.42% of those who received the Pfizer or AstraZeneca vaccine developed antibodies from 28 to 34 days after their first dose. "A unique dose of the anti-astrazeneca or Pfizer vaccine leads to high antibody levels in people who have not yet been Covid-19", says researchers.
The antibodies have also developed the participants who have received the vaccine against Pfizer, but four weeks after the first dose of vaccine, the antibody rates were equivalent for both sizes.
"More than nine out of 10 adults in the United Kingdom who had the Pfizer or Astrazeneca vaccineProduct antibodies against the virus Within one month of their first shot, "the main author of studyMaddie Shrotri said in a statement. "To what extent these vaccines are remarkable, given the speed in which they have been developed. It is a real feat of science in the face of the most devastating pandemic for a century."
RELATED:For more information up to date, sign up for our daily newsletter.
Antibody levels after the first dose of a single vaccine were not as high in some recipients. For example, researchers say they "have found evidence that antibody levels were lower with the more and more age after the first dose of vaccine". And people with various long-term health conditions such as diabetes, heart disease, cancer and those on immunosuppressive therapies have also experienced lower antibody levels following the first dose.
"These differences observed in antibody levels emphasize the importance of ongoing public health preventive measures such as adult social distancing that had only one dose of vaccine, particularly those which are older and older. more vulnerable, "says researchers in the study.
The conclusion, then, is not that there is no clearNeed the second dose of these vaccines. The researchers reported that an even higher number of people-99.08% of antibodies developed at seven to 14 days after receiving their second vaccine shot. The study also found that high antibody levels were "observed for almost all individuals" after the second dose of the anti-Pfizer or AstraZeneca vaccine, including those with long-term health conditions. According to researchers, it reinforces the importance of complete coverage of this second dose for the population. "
RELATED:The effect on one side that is much more common with Pfizer, data data.
